Related Experiment Video
Updated: Jun 3, 2025
09:56
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
457
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical
Yi-Jiun Su1,2, Anne Marijn Kramer1, Mark P Hamilton1,3
1Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.
Cancer Discovery
|January 8, 2025
Abstract
Significance:
Late leukapheresis (>6 months after CAR19) resulted in less residual CAR19, higher CAR22 CD4+ naïve T and TCM cells, less TEM cells, and higher CD8+ TCM cells, but similar clinical outcomes to those with early leukapheresis. CAR22 responses were associated with higher transduction efficiency and CD8+ TCM and less CD8+ TEM cells.
